NKG2D
NKG2D Molekülinformation
| Englischer Name | NKG2-D type II integral membrane protein | Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 9 | Target-Alias | Killer cell lectin-like receptor subfamily K member 1，NK cell receptor D，NKG2-D-activating NK receptor，CD314，D12S2489E，KLR，DNA Segment On Chromosome 12 (Unique) 2489 Expressed Sequence，Killer Cell Lectin Like Receptor K1，NKG2-D，Killer Cell Lectin-Like Receptor Subfamily K， Member 1，KLRK1，CD314 Antigen |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical | ||
| Englischer Name | NKG2-D type II integral membrane protein |
| Target-Alias | Killer cell lectin-like receptor subfamily K member 1，NK cell receptor D，NKG2-D-activating NK receptor，CD314，D12S2489E，KLR，DNA Segment On Chromosome 12 (Unique) 2489 Expressed Sequence，Killer Cell Lectin Like Receptor K1，NKG2-D，Killer Cell Lectin-Like Receptor Subfamily K， Member 1，KLRK1，CD314 Antigen |
| Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 9 |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical |
NKG2D Produktliste
- Attribut
Protein (7)
- Produktbibliothek
Online (7)
- Spezies
Human (6)Cynomolgus (1)
- Etikett
Fc Tag (2)His Tag (2)Mouse IgG Fc Tag (1)Fc Tag & Avi Tag (1)His Tag & Avi Tag (1)
- Marker
Unconjugated (4)FITC Labeled (1)Biotin-labeled (2)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
HOT NKD-H5245 |  Human | HEK293 | Human NKG2D / CD314 Protein, His Tag, low endotoxin (HPLC verified) |  |  |  |  In den Warenkorb legen |
HOT NKD-H5259 | Human | HEK293 | Human NKG2D / CD314 Protein, Mouse IgG2a Fc Tag |  | | | In den Warenkorb legen |
HOT NKD-H5265 | Human | HEK293 | Human NKG2D / CD314 Protein, Fc Tag (MALS verified) |  | | | In den Warenkorb legen |
HOT NKD-H82Q3 | Human | HEK293 | Biotinylated Human NKG2D / CD314 Protein, Avitag™,His Tag (MALS verified) |  | | | In den Warenkorb legen |
HOT NKD-C5248 |  Cynomolgus | HEK293 | Cynomolgus NKG2D / CD314 Protein, His Tag, low endotoxin |  | | | In den Warenkorb legen |
| Human | HEK293 | Biotinylated Human NKG2D / CD314 Protein, Avitag™,Fc Tag (MALS verified) |  | | | In den Warenkorb legen | |
| Human | HEK293 | FITC-Labeled Human NKG2D / CD314 Protein, Fc Tag |  | | | In den Warenkorb legen |
Gesamtmenge7
- 1
NKG2D Molekülhintergrund
NKG2D is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors, also known as KLRK1, CD314, D12S2489E, KLR and killer cell lectin like receptor K1. NKG2D itself forms a homodimer whose ectodomains serve for ligand binding. NKG2D is a major recognition receptor for the detection and elimination of transformed and infected cells as its ligands are induced during cellular stress, either as a result of infection or genomic stress such as in cancer. In NK cells, NKG2D serves as an activating receptor, which itself is able to trigger cytotoxicity. The function of NKG2D on CD8+ T cells is to send co-stimulatory signals to activate them.
NKG2D Molekülalias
NKG2D,CD314,KLRK1,NK cell receptor D
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Tesnatilimab | IPH-2301; IPH-23XX; JNJ-4500; JNJ-64304500; NNC-0142-002; NNC-0142-0002; NNC-0142-0000-0002; NN-8555 | Phase 2 Clinical | Innate Pharma | Alopecia Areata; Arthritis, Rheumatoid; Celiac Disease; Crohn Disease; Inflammation | Details |
| NKG2D-ACE2 CAR-NK cell therapy (Sidemu Biotechnology Technology) | Phase 2 Clinical | Chongqing Sidemu Biotechnology Technology Co Ltd | Coronavirus Disease 2019 (COVID-19); Hematologic Neoplasms | Details | |
| NKG2D CAR-T Cell | Phase 1 Clinical | Hangzhou Cheetah Cell Therapeutics Co Ltd | Colorectal Neoplasms; Leukemia, Myeloid, Acute; Neoplasm Metastasis; Ovarian Neoplasms | Details | |
| anti-NKG2D CAR NK-cell therapy (Xinxiang Medical University) | Phase 1 Clinical | Xinxiang Medical University | Solid tumours | Details | |
| Anti-NKG2D CAR-NK cells therapy (CNK Cell Therapeutics) | Phase 1 Clinical | CNK Cell Therapeutics Co Ltd | Solid tumours | Details | |
| Anti-NKG2D CAR-T cell therapy (CNK Cell Therapeutics) | Phase 1 Clinical | Hangzhou CNK Therapeutics Co Ltd | Pancreatic Neoplasms; Solid tumours | Details | |
| NKG2D CAR-T Cell therapy (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Colorectal Neoplasms; Leukemia, Myeloid, Acute | Details | |
| Anti-NKG2D chimeric antigen receptor natural killer cell therapy (Hangzhou Cheetah Cell Therapeutics) | Clinical | Leukemia, Myeloid, Acute; Ovarian Neoplasms | Details | ||
| NKG2D CAR-T cell therapy (Uwell Biopharma) | UWN2D | Clinical | Uwell Biopharma | Neoplasms | Details |
- Produktliste
- Klinische Arzneimittelinformation